The FDA is reviewing an sBLA for nogapendekin alfa inbakicept-pmln plus BCG to treat BCG-unresponsive NMIBC with papillary disease without CIS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results